Burosumab (Crysvita®). HTA ID: 23005

Assessment Status NCPE assessment ongoing
HTA ID 23005
Drug Burosumab
Brand Crysvita®
Indication Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients.
Assessment Process
Rapid review commissioned 03/02/2023
Rapid review completed 14/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/03/2023
Pre-submission consultation with Applicant 13/06/2023
Full submission received from Applicant 19/09/2023
Preliminary review sent to Applicant 06/03/2024
NCPE assessment re-commenced 05/04/2024
Follow-up to preliminary review sent to Applicant 18/04/2024
NCPE assessment re-commenced 24/04/2024
Additional follow-up to Preliminary Review sent to Applicant 25/04/2024
NCPE assessment re-commenced 01/05/2024
Factual accuracy sent to Applicant 07/06/2024
NCPE assessment re-commenced 14/06/2024